Dialog window

Products

Sherpa

Drafter

Reviewer

Researcher

Audiences

MedTech

Startups

Consultants

Guideways.ai

About us

Technology

FAQ

Trust

News & Insights

Contact us

Login
Book a demo
Register now
Dialog window

Products

Sherpa

Drafter

Researcher

Reviewer

Audiences

MedTech

Startups

Consultants

Guideways.ai

About us

Technology

FAQ

Trust

News & Insights

Contact us

Login
Book a demo
Register now
  • ≡

☰

Why MedTech VCs should focus on Regulatory Predictability to Unlock Returns

Why MedTech VCs should focus on Regulatory Predictability to Unlock Returns

by Alexander Habermeier | Mar 26, 2026 | Blog

In my recent open letter to founders, “The MedTech Valley of Death”[8], I made a blunt assertion. Eliminating unforced regulatory errors to secure a 30 percent faster FDA clearance is the ultimate survival lever for an early-stage MedTech CEO. But...
Navigating the Medtech Maze: Insights from 5 Founders on Regulatory Momentum

Navigating the Medtech Maze: Insights from 5 Founders on Regulatory Momentum

by Alexander Habermeier | Mar 6, 2026 | Blog, News

By Alexander Habermeier What does building ambitious health technology look like when regulatory approval is part of the equation from day one? On February 12th, during the Guideways Launch Event in Utrecht, we gathered a group of innovators who are moving the needle...
The MedTech Valley of Death: Why a 30% Faster FDA Clearance is your best lever for survival

The MedTech Valley of Death: Why a 30% Faster FDA Clearance is your best lever for survival

by Alexander Habermeier | Feb 22, 2026 | Blog

By Alexander Habermeier There is a brutal reality in the current medical device ecosystem that nobody wants to talk about during pitch meetings. Out of every ten brilliantly engineered devices (devices just like yours) eight or nine are dying before reaching patients...
Navigating FDA Medical Device Regulations Without Losing Regulatory Intent

Navigating FDA Medical Device Regulations Without Losing Regulatory Intent

by admin | Jan 12, 2026 | Blog

Compliance vs. regulatory intent In highly regulated industries, there is a temptation to treat FDA guidance as a checklist. However, experienced reviewers know that regulatory intent matters more than rote compliance. The FDA’s guidance on clinical decision support...
Why Navigating FDA Medical Device Regulations Fails Long Before Submission

Why Navigating FDA Medical Device Regulations Fails Long Before Submission

by admin | Jan 7, 2026 | Blog

Most regulatory problems are locked in early Medical device executives often focus on the moment of submission, yet many delays stem from decisions made months or years earlier. The FDA’s average 510(k) submission now exceeds 1.000 pages, even though it is the...
AI to Navigate FDA Medical Device Regulations in the Age of Foundation Models

AI to Navigate FDA Medical Device Regulations in the Age of Foundation Models

by admin | Jan 2, 2026 | Blog

Why the AI hype has not solved regulatory navigation yet Large‑language models and other foundation models have made it possible to search and summarise FDA guidance at unprecedented speed. However, subject matter experts note that they do not automatically translate...

Recent Posts

  • AI Regulatory Affairs Agents for Medical Device Teams: What They Are, How They Work and Where They Fit 
  • Introducing MDR: Faster Access to EU Markets, Without the Bottlenecks
  • Guideways launches AI platform to get life-changing medical devices to patients years faster
  • Why MedTech VCs should focus on Regulatory Predictability to Unlock Returns
  • Navigating the Medtech Maze: Insights from 5 Founders on Regulatory Momentum

Recent Comments

No comments to show.

Solutions

MedTech
Consultants

Products

Sherpa
Drafter
Reviewer
Researcher

Guideways.ai

Home
About us
Technology

Contact

info@guideways.ai

Privacy policy    |      Cookies